Profusa (NASDAQ:PFSA) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Profusa (NASDAQ:PFSA) to a sell rating in a research report report published on Saturday.

Separately, Weiss Ratings downgraded Profusa from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Profusa presently has a consensus rating of “Sell”.

Profusa Trading Down 27.9%

Profusa stock opened at $5.46 on Friday. Profusa has a 1-year low of $3.22 and a 1-year high of $5,190.00. The company has a fifty day simple moving average of $9.48 and a 200 day simple moving average of $74.62. The company has a market cap of $3.33 million, a P/E ratio of -0.00 and a beta of 0.52.

Profusa (NASDAQ:PFSA) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 10,602 shares of Profusa stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total transaction of $37,743.12. Following the completion of the transaction, the insider directly owned 18,549 shares in the company, valued at approximately $66,034.44. The trade was a 36.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders purchased 4,308 shares of company stock valued at $16,594 over the last ninety days. Company insiders own 0.76% of the company’s stock.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.